SCHEMBL1262385

SCHEMBL1262385

CCCCCC(CO)OO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
CYP2D6 P10635 2/20 0.42
SPHK1 Q9NYA1 1/20 0.42
GMNN O75496 1/20 0.42
POLB P06746 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42
BLM P54132 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CETP P11597 1/20 0.42
HTT P42858 1/20 0.42
UBE2N P61088 1/20 0.42
ALDH1A1 P00352 2/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11116511 0.98 LMNA (0.54) LMNAMAPTMAPK1CYP2D6SPHK1
SCHEMBL1262228 0.98 LMNA (0.54) LMNAMAPTMAPK1CYP2D6SPHK1
SCHEMBL1261782 0.98 LMNA (0.54) LMNAMAPTMAPK1CYP2D6SPHK1
SCHEMBL1261857 0.93
SCHEMBL31436265 0.85 LMNA (0.48) LMNAMAPTSPHK1FDPSSMPD1
SCHEMBL27476110 0.85 LMNA (0.48) LMNAMAPTSPHK1FDPSSMPD1
SCHEMBL6275484 0.83 LMNA (0.46) LMNAMAPTSPHK1FDPSSMPD1
SCHEMBL8672416 0.83 LMNA (0.41) LMNAMAPTSPHK1TP53ALDH1A1
SCHEMBL9974990 0.82
SCHEMBL4076477 0.81 LMNA (0.56) LMNAMAPTMAPK1CYP2D6SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7880038-B2 complexing a tungsten boride and molybdenum boride, a phosphate compound, Mo and W metal, hydrogen peroxide and an amine oxide to form a catalyst, reacting an olefin with H2O2 in the pH 0 to 2 or more, in presence of above catalyst to produce carbonyl compounds by oxidative breaking of C-C bond of olefin SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-01 US disclosed
EP-1618953-B1 USE OF A METAL CATALYST SUMITOMO CHEMICAL CO (JP) 2010-12-08 EP disclosed
US-7132092-B2 Metallized mesoporous silicate and method of oxidation with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-11-07 US disclosed
US-20060211891-A1 Metal catalyst and its use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1618953-A1 METAL CATALYST AND ITS USE Sumitomo Chemical Company, Limited (JP) 2006-01-25 EP disclosed
US-20050090688-A1 Metallized mesoporous silicate and method of oxidation with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-28 US disclosed
EP-1473275-A1 METALLIZED MESOPOROUS SILICATE AND METHOD OF OXIDATION WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211891-A1 Metal catalyst and its use SOD1, NOX4, MVD LMNA 4399/4885MAPT 3469/4885MAPK1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.